In conclusion, we show here for the first time that CPS is able to target mutp53 proteins and in particular R175 mutation that is the third most common missense p53 mutation in human cancer and R273 that is one of the p53 mutation responsible of resistance to antitumor drugs [4], reactivating wild-type p53 oncosuppressor function. The gene discussed is CAD; the disease is cancer.